| Jun 13 |
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
|
| May 30 |
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
|
| May 22 |
Dyne Therapeutics prices $325.5M stock offering
|
| May 22 |
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
|
| May 21 |
Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials
|
| May 21 |
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
|
| May 20 |
Why Is Dyne Therapeutics Stock Soaring On Monday?
|
| May 20 |
Dyne Therapeutics announces underwritten proposed offering of common stock
|
| May 20 |
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
|
| May 20 |
Dyne Therapeutics announces data from early stage trials of muscular dystrophy treatments
|
